HIV Vaccine Research and Design (HIVRAD)
This grant mechanism accepts projects too advanced for the exploratory Innovation Grant Program, but not yet sufficiently advanced for the production-oriented Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant Program.
Applicants may target any area of AIDS vaccine research, including animal model development, studies of HIV immunogen structure, studies of mechanisms of vaccine action, development of viral and bacterial vectors, studies of immune responses using existing vaccine cohort samples, or studies that evaluate new assays of immunity. Neither human clinical studies nor vaccine research focused solely on therapeutic applications are supported by this program. Innovation grantees and investigators with vaccine concepts supported by preliminary data are encouraged to apply. Applications from foreign institutions are also encouraged. HIVRAD grants will be limited to five years of funding. Applicants should discuss questions regarding appropriateness of their research for the HIVRAD grant mechanism and/or funding issues with the NIAID/DAIDS program contact.
HIVRAD Contact Information
James Bradac, Ph.D.
Phone: 301-435-3754
Fax: 301-402-3684
E-mail: jbradac@niaid.nih.gov
June 23, 2008
Current Awardees
Hildegund Ertl
HIV-1 vaccine based on chimp serotypes of adenovirus
Wistar Institute
Ellis Reinhertz
Structural approaches to vaccine development
Dana-Farber Cancer Institute
Michael Keefer
HSV-1 amplicon vectors for HIV vaccine delivery
University of Rochester
Judy Lieberman
Engineered Listeria monocytogenes as an AIDS vaccine
CBR Institute for Biomedical Research
Shiu-Lok Hu
Combined approach to broadly protective AIDS vaccine
University of Washington
Christopher Miller
Mechanisms of protection in live-attenuated AIDS vaccine
University of California, Davis
Barton Haynes
Centralized HIV-1 genes as vaccines
Duke University
Robert Whalen
Development of novel immunogens for vaccines to HIV-1
Maxygen, Inc.
David Knipe
Herpesvirus as vaccine vectors for AIDS
Harvard Medical School
Susan Barnett
Targeting neutralizing epitopes in the HIV envelope
Chiron Corporation/Novartis
R. Paul Johnson
Mechanisms of protective immunity induced by live attenuated SIV vaccine
Harvard Medical School
David Weiner
DNA vaccine for induction of mucosal responses
University of Pennsylvania
Ruth Ruprecht
Vaccination against mucosal HIV Clade C transmission
Harvard Medical School
back to top